Cocrystal Pharma is a biotechnology company engaged in discovering and developing antiviral therapeutics as treatments for serious and/or chronic viral diseases. Co. is developing antiviral therapeutics that inhibit the viral replication function of RNA viruses causing acute and chronic viral diseases. Co.'s targets include treating influenza virus, coronavirus and norovirus infections by discovering and developing drug candidates targeting the viral replication process. Additionally, Co. is targeting to decrease the duration of Hepatitis C virus (HCV) therapy by developing its drug candidate targeting HCV RNA-dependent RNA polymerase enzyme through partnerships and/or licensing activities. The COCP stock yearly return is shown above.
The yearly return on the COCP stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the COCP annual return calculation with any dividends reinvested as applicable (on ex-dates).
|